Fig. 7 | Scientific Reports

Fig. 7

From: A novel zinc finger protein gene signature for prognostic prediction, tumor microenvironment characterization, and therapeutic response in uterine corpus endometrial carcinoma

Fig. 7

Drug sensitivity analysis of high and low ZNF score groups in TCGA-UCEC cohort. (A–H) Differences in the IC50 of anti-tumor drugs between different ZNF score groups. (A) Foretinib, (B) Palbociclib, (C) Selumetinib, (D) Trametinib, (E) Bortezomib, (F) Ibrutinib, (G) Savolitinib, (H) Sepantronium bromide. (I–P) Correlation between anti-tumor drugs and ZNF score. (I)Foretinib, (J) Palbociclib, (K) Selumetinib, (L) Trametinib, (M) Bortezomib, (N) Ibrutinib, (O) Savolitinib, (P) Sepantronium bromide. IC50, half-maximal inhibitory concentration. (*, **, ***, **** represent P < 0.05, P < 0.01, P < 0.001, P < 0.0001, respectively.)

Back to article page